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the formation of lipid-laden macrophage foam cells within the vessel wall. IL-37 is recognized as
an important anti-inflammatory cytokine expressed especially by immune cells. This study was
undertaken to elucidate the role of macrophage-expressed IL-37 in reducing the production and
effects  of  proinflammatory  cytokines,  preventing  foam  cell  formation,  and  reducing  the
development of atherosclerosis. Expression of human IL-37 was achieved with a macrophage-
specific  overexpression system, using the CD68 promoter in mouse primary bone marrow-
derived macrophages via retroviral transduction. Macrophage IL-37 expression in vitro resulted
in decreased mRNA (e.g., IL-1B, IL-6, and IL-12) and secreted protein production (e.g., IL-6, M-
CSF, and ICAM-1) of key inflammatory mediators. IL-37 expression also inhibited macrophage
proliferation, apoptosis, and transmigration, as well as reduced lipid uptake, compared with
controls in vitro. The in vivo effects of macrophage-expressed IL-37 were investigated through
bone  marrow  transplantation  of  transduced  hematopoietic  stem  cells  into  irradiated
atherosclerosis-prone Ldlr2/2 mice. After 10 wk on a high-fat/high-cholesterol diet, mice with IL-
37-expressing macrophages showed reduced disease pathogenesis, which was demonstrated by
significantly less arterial plaque development and systemic inflammation compared with control
mice.  The  athero-protective  effect  of  macrophage-expressed  IL-37  has  implications  for
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